1. Home
  2. SPRO vs GSIW Comparison

SPRO vs GSIW Comparison

Compare SPRO & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.34

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

GSIW

Garden Stage Limited

HOLD

Current Price

$0.14

Market Cap

33.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
GSIW
Founded
2013
2016
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.7M
33.9M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
SPRO
GSIW
Price
$2.34
$0.14
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
328.9K
354.9K
Earning Date
11-13-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,549,000.00
$5,368,221.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
283.23
52 Week Low
$0.51
$0.09
52 Week High
$3.22
$1.79

Technical Indicators

Market Signals
Indicator
SPRO
GSIW
Relative Strength Index (RSI) 49.98 43.40
Support Level $2.26 $0.14
Resistance Level $2.39 $0.15
Average True Range (ATR) 0.08 0.01
MACD -0.00 -0.00
Stochastic Oscillator 62.50 23.16

Price Performance

Historical Comparison
SPRO
GSIW

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

Share on Social Networks: